Sutro Biopharma STRO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -120%+34.5pp | -154.5%+21.1pp | -175.7%+20.6pp | -196.3%+181pp | -376.9%+7.5pp | |
| Net margin | -154.2%+32.2pp | -186.5%+18.7pp | -205.2%-5.4pp | -199.8%+169pp | -369.1%-2.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.3×0.0× | 0.3×+0.1× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.1×+1.1× | 2×-0.5× | 2.5×-0.6× | 3.1×+1.0× | 2.2×-0.4× | |
| Per Share | ||||||
| Book value per share | -$5.11+67.2% | -$15.59-1,416% | -$1.03-171% | -$0.38+87.7% | -$3.09-154% | |
| Valuation | ||||||
| Market capitalization | $489.66M+624% | $98.57M+33.9% | $73.62M+6.0% | $69.46M+27.4% | $54.5M-64.1% | |
| Price / sales | 4.9×+3.9× | 1×+0.3× | 0.7×0.0× | 0.7×-0.2× | 0.8×-1.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sutro Biopharma's ratios come from?
- Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
